Showing results (1161-1170 of 3,351) with videos related to

Sort By:
Pageof 336
Pharmacoeconomics|November 16, 2017
The Assessment for Disinvestment of Intramuscular Interferon Beta for Relapsing-Remitting Multiple Sclerosis in BrazilLivia Lovato Pires de Lemos, Augusto Afonso Guerra Júnior, Marisa Santos, et al.
Pharmacoeconomics|January 1, 2019
Evaluating Cost-Effectiveness Models for Pharmacologic Interventions in Adults with Heart Failure: A Systematic Literature ReviewGian Luca Di Tanna, Anna Bychenkova, Frank O'Neill, et al.
Pharmacoeconomics|November 13, 2019
Correction to: A Budget Impact and Cost Per Additional Responder Analysis for Baricitinib for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors in the USAElizabeth Wehler, Natalie Boytsov, Claudia Nicolay, et al.
Pharmacoeconomics|December 3, 2019
Value in Hepatitis C Virus Treatment: A Patient-Centered Cost-Effectiveness AnalysisT Joseph Mattingly, Julia F Slejko, Eberechukwu Onukwugha, et al.
Pharmacoeconomics|February 10, 2019
A Flexible Open-Source Decision Model for Value Assessment of Biologic Treatment for Rheumatoid ArthritisDevin Incerti, Jeffrey R Curtis, Jason Shafrin, et al.
Pharmacoeconomics|November 26, 2019
Transferability of Economic Evaluations of Treatments for Advanced MelanomaClaire Gorry, Laura McCullagh, Michael Barry
Pharmacoeconomics|December 23, 2017
Australian Utility Weights for the EORTC QLU-C10D, a Multi-Attribute Utility Instrument Derived from the Cancer-Specific Quality of Life Questionnaire, EORTC QLQ-C30Madeleine T King, Rosalie Viney, A Simon Pickard, et al.
Pharmacoeconomics|February 25, 2018
Author Correction to: Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment StrategyAmir Ansaripour, Carin A Uyl-de Groot, W Ken Redekop
Pharmacoeconomics|February 26, 2018
The Australian Managed Entry Scheme: Are We Getting it Right?Haitham W Tuffaha, Paul A Scuffham
Pharmacoeconomics|March 21, 2018
Cost-Effectiveness Analysis of Lesinurad/Allopurinol Versus Febuxostat for the Management of Gout/Hyperuricemia in ItalyM Ruggeri, M Basile, C Drago, et al.
Pageof 336